Compare Stocks: STRO, ANAB, ZYME, and NTLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.92 -1.6%	$57.66	$11.40 ▼ $72.36	$1.69B	0.72	738,660 shs	293,127 shs
NTLA Intellia Therapeutics	$12.10 +0.7%	$13.59	$7.95 ▼ $28.25	$1.69B	1.81	5.38 million shs	1.68 million shs
STRO Sutro Biopharma	$21.26 -15.1%	$27.24	$7.15 ▼ $43.85	$352.28M	1.55	254,389 shs	1.35 million shs
ZYME Zymeworks	$24.95 +2.6%	$23.99	$13.06 ▼ $29.75	$1.77B	1.15	670,253 shs	411,937 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+4.33%	+4.85%	-12.83%	-7.69%	+189.35%
NTLA Intellia Therapeutics	0.00%	+6.18%	-15.47%	-15.83%	+11.92%
STRO Sutro Biopharma	-1.92%	-2.45%	-15.78%	-36.77%	+224.10%
ZYME Zymeworks	+0.66%	+6.71%	-6.03%	-1.02%	+95.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$56.92 -1.6%	$57.66	$11.40 ▼ $72.36	$1.69B	0.72	738,660 shs	293,127 shs
NTLA Intellia Therapeutics	$12.10 +0.7%	$13.59	$7.95 ▼ $28.25	$1.69B	1.81	5.38 million shs	1.68 million shs
STRO Sutro Biopharma	$21.26 -15.1%	$27.24	$7.15 ▼ $43.85	$352.28M	1.55	254,389 shs	1.35 million shs
ZYME Zymeworks	$24.95 +2.6%	$23.99	$13.06 ▼ $29.75	$1.77B	1.15	670,253 shs	411,937 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+4.33%	+4.85%	-12.83%	-7.69%	+189.35%
NTLA Intellia Therapeutics	0.00%	+6.18%	-15.47%	-15.83%	+11.92%
STRO Sutro Biopharma	-1.92%	-2.45%	-15.78%	-36.77%	+224.10%
ZYME Zymeworks	+0.66%	+6.71%	-6.03%	-1.02%	+95.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	44.06% Upside
NTLA Intellia Therapeutics	2.35	Hold	$20.85	72.35% Upside
STRO Sutro Biopharma	2.92	Moderate Buy	$52.00	144.59% Upside
ZYME Zymeworks	2.82	Moderate Buy	$40.75	63.33% Upside

Current Analyst Ratings Breakdown

Latest STRO, ANAB, ZYME, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	ZYME Zymeworks	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $44.00
8/10/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	ZYME Zymeworks	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$46.00
8/7/2026	NTLA Intellia Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Outperform	$24.00
8/7/2026	ZYME Zymeworks	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $40.00
8/7/2026	STRO Sutro Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$48.00
8/7/2026	ZYME Zymeworks	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $32.00
8/5/2026	STRO Sutro Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $51.00
7/17/2026	NTLA Intellia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	7.18	N/A	N/A	$1.34 per share	42.48
NTLA Intellia Therapeutics	$59.51M	28.41	N/A	N/A	$5.19 per share	2.33
STRO Sutro Biopharma	$99.61M	3.54	N/A	N/A	($15.43) per share	-1.38
ZYME Zymeworks	$37.13M	47.69	N/A	N/A	$1.13 per share	22.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	17.51	N/A	-11.53%	N/A	-7.75%	N/A
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	N/A
STRO Sutro Biopharma	-$191.09M	-$11.04	N/A	N/A	N/A	-154.21%	N/A	-69.20%	N/A
ZYME Zymeworks	-$81.13M	-$2.02	N/A	56.70	N/A	-405.31%	-72.30%	-37.18%	N/A

Latest STRO, ANAB, ZYME, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	STRO Sutro Biopharma	-$2.19	-$2.33	-$0.14	-$2.33	$11.96 million	$9.84 million
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$4.59 million
5/14/2026	Q1 2026	STRO Sutro Biopharma	-$2.7363	-$2.94	-$0.2037	-$2.94	$8.89 million	$14.52 million
5/12/2026	Q1 2026	ANAB AnaptysBio	-$0.6436	-$1.84	-$1.1965	-$1.84	$18.86 million	$25.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
NTLA Intellia Therapeutics	N/A	6.65	6.65
STRO Sutro Biopharma	N/A	3.12	3.12
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
NTLA Intellia Therapeutics	88.77%
STRO Sutro Biopharma	96.99%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
NTLA Intellia Therapeutics	3.50%
STRO Sutro Biopharma	1.80%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
NTLA Intellia Therapeutics	600	139.72 million	134.83 million	Optionable
STRO Sutro Biopharma	240	16.57 million	16.27 million	Optionable
ZYME Zymeworks	460	70.96 million	47.18 million	N/A

STRO, ANAB, ZYME, and NTLA Headlines

Recent News About These Companies

Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright

August 12 at 6:11 AM | marketbeat.com

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

August 11 at 10:31 AM | zacks.com

HC Wainwright Issues Negative Outlook for Zymeworks Earnings

August 11 at 7:57 AM | marketbeat.com

Zymeworks Steps Up Investor Outreach with September Conference Lineup

August 11 at 6:51 AM | tipranks.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11 at 6:11 AM | financialpost.comF

Zymeworks Inc. to Participate in Upcoming Investor Conferences in September

August 11 at 6:11 AM | quiverquant.comQ

Zymeworks (NASDAQ:ZYME) Update Puts Antibody Strategy In Focus

August 9 at 7:58 AM | kalkinemedia.comK

Truist Financial Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock

August 9 at 4:23 AM | americanbankingnews.com

Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME

August 9 at 3:27 AM | marketbeat.com

Wells Fargo Remains a Buy on Zymeworks (ZYME)

August 8, 2026 | theglobeandmail.com

HC Wainwright Has Negative Outlook for Zymeworks Q3 Earnings

August 8, 2026 | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Issues Earnings Results, Misses Expectations By $0.05 EPS

August 7, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

August 7, 2026 | marketbeat.com

What is HC Wainwright's Forecast for Zymeworks Q2 Earnings?

August 7, 2026 | marketbeat.com

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

What is HC Wainwright's Estimate for Zymeworks Q3 Earnings?

August 6, 2026 | marketbeat.com

Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME

August 6, 2026 | marketbeat.com

Zymeworks Inc. (NASDAQ:ZYME) Receives $37.33 Average Price Target from Brokerages

August 6, 2026 | americanbankingnews.com

Perceptive Advisors LLC Increases Stock Holdings in Zymeworks Inc. $ZYME

August 2, 2026 | marketbeat.com

Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 1, 2026 | marketbeat.com

Zymeworks (ZYME) Receives a Buy from B. Riley Securities

July 31, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STRO, ANAB, ZYME, and NTLA Company Descriptions

AnaptysBio NASDAQ:ANAB

$56.92 -0.95 (-1.64%)

As of 03:58 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Intellia Therapeutics NASDAQ:NTLA

$12.10 +0.08 (+0.67%)

As of 03:58 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$21.26 -3.78 (-15.10%)

As of 03:58 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Zymeworks NASDAQ:ZYME

$24.95 +0.63 (+2.59%)

As of 03:57 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STRO, ANAB, ZYME, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STRO, ANAB, ZYME, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STRO, ANAB, ZYME, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STRO, ANAB, ZYME, and NTLA Company Descriptions

AnaptysBio NASDAQ:ANAB

Intellia Therapeutics NASDAQ:NTLA

Sutro Biopharma NASDAQ:STRO

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STRO, ANAB, ZYME, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STRO, ANAB, ZYME, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STRO, ANAB, ZYME, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

STRO, ANAB, ZYME, and NTLA Company Descriptions

AnaptysBio NASDAQ:ANAB

Intellia Therapeutics NASDAQ:NTLA

Sutro Biopharma NASDAQ:STRO

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools